Sumitomo Dainippon Pharma Co., Ltd. Announces Changes in Board of Directors, Audit & Supervisory Board and Other Key Positions
May 11, 2018 at 06:30 am
Share
Sumitomo Dainippon Pharma Co., Ltd. announced that in its meeting held on May 11, 2018, the Board of Directors appointed the following candidates for new members of the Board of Directors as well as the Audit & Supervisory Board. Saeko Arai (President, Acuray Inc.): The new member of the Board of Directors who will take office as of June 19, 2018 subject to the approval at the general shareholders' meeting scheduled for the same date. Retiring Members of the Board of Directors: Hiroshi Sato (currently Member, Board of Directors). New Members of the Audit & Supervisory Board: Takashi Kutsunai (currently Senior Director, Internal Auditing) Yoshio Iteya (attorney at law). The new members of the Audit & Supervisory Board who will take office as of June 19, 2018 subject to the approval at the general shareholders' meeting scheduled for the same date. Retiring Members of the Audit & Supervisory Board: Nobuo Takeda (currently Member, Audit & Supervisory Board) Harumichi Uchida (currently Outside Audit & Supervisory Board Member). The company also announced the following Changes in Personnel, effective June 19, 2018: Senior Director, Internal Auditing; Fumihiro Nishi (currently Senior Director, Corporate Secretariat & Industry Affairs); Senior Director, External Affairs; Corporate Secretariat & Industry Affairs; Tomokazu Nagano (currently Senior Director, External Affairs).
Sumitomo Pharma Co., Ltd. (formerly Sumitomo Dainippon Pharma Co., Ltd.) specializes in development, manufacturing and marketing of pharmaceutical products. Net sales break down by family of products as follows:
- pharmaceuticals (92.9%): for cardiovascular, gastrointestinal and infectious diseases, central nervous systems disorders and allergies treatment;
- other (7.1%): veterinary drugs, food additives, industrial chemical products, etc.
Net sales are distributed geographically as follows: Japan (39.8%), the United States (50.4%), North America (0.9%) and other (8.9%).